Rounding down the figures: Natera, Inc. (NASDAQ: NTRA)

On 09 Jan 2020, Natera, Inc stock identified change of 202.65% away from 52-week low price and recently located move of -17.75% off 52-week high price. NTRA stock has been recorded -8.31% away from 50 day moving average and 14.31% away from 200 day moving average. Moving closer, we can see that shares have been trading -4.02% off 20-day moving average. The Healthcare sector company, Natera, Inc. noticed change of -2.08% to $33.65 along volume of 455587 shares in recent session compared to an average volume of 753.37K.

Natera, Inc. (NASDAQ:  NTRA) recently stated financial results for the third quarter ended September 30, 2019 and provided an update on recent business progress.

Recent Accomplishments & Highlights

Generated total revenues of $77.9M in the third quarter of 2019 contrast to $65.3M in the third quarter of 2018, a raise of 19%.

Processed over 200,000 tests in the third quarter of 2019, contrast to about 167,000 tests processed in the third quarter of 2018, a raise of about 20%.

Processed about 136,000 Panorama tests in the third quarter of 2019, contrast to about 106,000 Panorama tests processed in the third quarter of 2018, a raise of about 28%.

Accessioned about 55,000 Horizon carrier screening (HCS) tests in the third quarter of 2019 contrast to about 44,000 HCS tests accessioned in the third quarter of 2018, a raise of about 25%.

Received positive draft local coverage decision from Medicare for reimbursement of Signatera™ in colorectal cancer.

Completed key technical and commercialization milestones with BGI Genomics.

Entered into joint venture to develop and commercialize personalized circulating tumor DNA monitoring assays with Foundation Medicine.

Successfully completed $230M follow-on equity offering.

Third Quarter Ended September 30, 2019 Financial Results

Total revenues were $77.9M in the third quarter of 2019 contrast to $65.3M for the third quarter of 2018, a raise of 19%. The increase in total revenues was driven primarily by increased sales of our Panorama and HCS tests. There were about 200,200 tests processed in the third quarter of 2019, including about 187,200 tests accessioned and 12,100 processed through the Constellation software platform (Constellation units), contrast to about 167,200 tests processed in the third quarter of 2018, including about 156,600 tests accessioned and 9,500 Constellation units, an overall increase of about 20%.

In the three months ended September 30, 2019, Natera recognized revenue on about 189,600 tests for which results were stated to consumers in the period (tests stated), including about 178,000 tests accessioned and 11,600 Constellation units, contrast to about 154,900 tests stated, including about 145,700 tests accessioned and 9,200 Constellation units, in the third quarter of 2018, which represents a raise of about 22%.

NTRA’s shares are at -1.13% for the quarter and driving a 196.78% return over the course of the past year and is now at -0.10% since this point in 2018.   The average volatility for the week at 4.13% and for month was at 4.66%. There are 78.54M shares outstanding and 73.97M shares are floated in market. Right now, the stock beta is 1.33.

 

Leave a Reply

Your email address will not be published. Required fields are marked *